RecruitingPhase 1NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OncoNano Medicine, Inc.
- Intervention
- ONM-501(drug)
- Enrollment
- 168 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (16)
- California Research Institute, Los Angeles, California, United States
- BRCR Global, Tamarac, Florida, United States
- Gabrail Cancer Center Research, Canton, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- Allegheny Health Network, Pittsburgh, Pennsylvania, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
- St Vincent's Hospital, Darlinghurst, New South Wales, Australia
- Cancer Care Wollongong, Wollongong, New South Wales, Australia
- University of the Sunshine Coast Clinical Trials, Buderim, Queensland, Australia
- Tasman Oncology Research, Southport, Queensland, Australia
- Princess Alexandra Hospital | Metro South Health, Woolloongabba, Queensland, Australia
- Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06022029 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.